Flt3 ligand promotes myeloid dendritic cell differentiation of human hematopoietic progenitor cells: Possible application for cancer immunotherapy

International Journal of Oncology

Volumn 30, Issue 6, 2007, Pages 1461-1468

  Harada, Sachio ^a,b   Kimura, Takafumi ^a   Fujiki, Hiroshi ^b   Nakagawa, Hitoshi ^c   Ueda, Yuji ^b   Itoh, Tsuyoshi ^b   Yamagishi, Hisakazu ^b   Sonoda, Yoshiaki ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^c KYOTO FIRST RED CROSS HOSPITAL   (Japan)

Author keywords

Cancer immunotherapy; Dendritic cell; Flt3 ligand; Hematopoietic progenitor cell

Indexed keywords

CD34 ANTIGEN; FLT3 LIGAND PROTEIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEMBRANE PROTEIN; THROMBOPOIETIN; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOLOGY; DENDRITIC CELL; FLOW CYTOMETRY; HUMAN; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; METHODOLOGY; MIXED LYMPHOCYTE CULTURE; MYELOID PROGENITOR CELL; NEOPLASM; T LYMPHOCYTE;

ANTIGENS, CD34; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; DENDRITIC CELLS; FLOW CYTOMETRY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MEMBRANE PROTEINS; MYELOID PROGENITOR CELLS; NEOPLASMS; T-LYMPHOCYTES; THROMBOPOIETIN;

EID: 34447265032     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.30.6.1461     Document Type: Article

References (48)

1. Miyani H, Dragowska W and Lansdorp PM: Lineage commitment of human hemopoiesis involves asymmetric cell division of multipotent progenitors and does not appear to be influenced by cytokines. J Cell Physiol 157: 579-586, 1993. (Pubitemid 23361187)
2. Zipori D: The renewal and differentiation of hemopoietic stem cells. FASEB J 6: 2691-2697, 1992.
3. Nutt SL, Thevenin C and Busslinger M: Essential functions of Pax-5 (BSAP) in pro-B cell development. Immunobiology 198: 227-235, 1997.
4. Metcalf D, Elliot MJ and Nicola NA: The excess numbers of peritoneal macrophages in granulocyte-macrophage colony-stimulating factor transgenic mice are generated by local proliferation. J Exp Med 175: 877-884, 1992.
5. Steinmann RM: The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 9: 271-296, 1991.
6. Cella M, Sallusto F and Lanzavecchia A: Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol 9: 10-16, 1997.
7. Banchereau J and Steinmann RM: Dendritic cells and the control of immunity. Nature 392: 245-252, 1998.
8. Salluso F and Lanzavecchia A: Mobilizing dendritic cells for tolerance, priming, and chronic inflammation. J Exp Med 189: 611-614, 1999.
9. Ardavin C, Wu L, Li CL and Shortman K: Thymic dendritic cells and T cells develop simultaneously in the thymus from a common precursor population. Nature 362: 761-763, 1993. (Pubitemid 23125982)
10. Shortman K, Vremec D, Corcoran LM, Georgopoulos K, Lucas K and Wu L: The linkage between T-cell and dendritic cell development in the mouse thymus. Immunol Rev 165: 39-46, 1998.
11. Inaba K, Inaba M, Romani N, et al: Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 176: 1693-1702, 1992.
12. Inaba K, Inaba M, Deguchi M, et al: Granulocytes, macrophages, and dendritic cells arise from a common major histocompatibility complex class II-negative progenitor in mouse bone marrow. Proc Natl Acad Sci USA 90: 3038-3042, 1993.
13. Young JW and Steinman RM: The hematopoietic development of dendritic cells: a distinct pathway for myeloid differentiation. Stem Cells 14: 3376-3387, 1996.
14. + human bone marrow cells and is involved in the proliferation of early progenitor/stem cells. Proc Natl Acad Sci USA 91: 459-463, 1994.
15. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP and Lemischka IR: Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity 3: 147-161, 1995.
16. Matthews W, Jordan CT, Wiegand GW, Pardoll D and Lemischka IR: A receptor tyrosine kinase specific to hematopoietic stem and progenitor cell-enriched populations. Cell 65: 1143-1152, 1991. (Pubitemid 121001328)
17. Brasel K, De Smedt T, Smith JL and Maliszewski CR: Generation of murine dendritic cells from flt3-ligand-supplemented bone marrow cultures. Blood 96: 3029-3039, 2000.
18. Gilliet M, Boonstra A, Paturel C, et al: The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3 ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 195: 953-958, 2002.
19. Gabbianelli M, Pelosi E, Motesoro E, et al: Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 86: 1661-1670, 1995.
20. + bone marrow progenitor cells in vitro. Blood 87: 5016-5026, 1996.
21. Ohmizono Y, Sakabe H, Kimura T, et al: Thrombopoietin augments ex vivo expansion of human cord blood-derived hematopoietic progenitors in combination with stem cell factor and flt3 ligand. Leukemia 11: 524-530, 1997.
22. Sonoda Y, Kimura T, Sakabe H, et al: Human flt3 ligand acts on myeloid as well as multipotential progenitors derived from purified CD34+ blood progenitors expressing different levels of c-kit protein. Eur J Haematol 58: 257-264, 1997.
23. Sakabe H, Kimura T, Zeng ZZ, et al: Haematopoietic action of flt3 ligand on cord blood-derived CD34-positive cells expressing different levels of flt3 or c-kit tyrosine kinase receptor: comparison with stem cell factor. Eur J Haematol 60: 297-306, 1998.
24. + progenitor cells isolated from healthy donor blood; growth factor combination determines proliferation rate and functional outcome. J Leukoc Biol 72: 321-329, 2002.
25. + dendritic cell precursor. Blood 93: 2244-2252, 1999.
26. Kimura T, Sakabe H, Tanimukai S, et al: Simultaneous activation of signals through gp130, c-kit, and interleukin-3 receptor promotes a trilineage blood cell production in the absence of terminally acting lineage-specific factors. Blood 90: 4767-4778, 1997.
27. Kimura T, Wang J, Minamiguchi H, et al: Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors. Stem Cells 18: 444-452, 2000.
28. Fujiki H, Kimura T, Minamiguchi H, et al: Role of human interleukin-9 as a megakaryocyte potentiator in culture. Exp Hematol 30: 1373-1380, 2002.
29. + cells selected by two different immunomagnetic beads systems. Leukemia 18: 566-574, 2004.
30. - cells assured by intra-bone marrow injection. Blood 101: 2924-2931, 2003.
31. + bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor α. J Exp Med 182: 1111-1119, 1995.
32. Lyman SD and Jacobsen SEW: c-kit ligand and Flt3 ligand: stem/progenitor cell factors with overlapping yet distinct activities. Blood 91: 1101-1134, 1998.
33. Banchereau J and Palucka AK: Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 5: 296-306, 2005. (Pubitemid 40516155)
34. Herrmann F, Brugger W, Kanz L and Mertelsmann R: In vivo biology and therapeutic potential of hematopoietic growth factors and circulating progenitor cells. Semin Oncol 19: 422-431, 1992.
35. Reinhard G, Marten A, Kiske SM, Feil F, Bieber T and Schmidt-Wolf IG: Generation of dendritic cell-based vaccines for cancer therapy. Br J Cancer 86: 1529-1533, 2002.
36. Sloand EM, Kim S, Maciejewski JP, et al: Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Bood 95: 2269-2274, 2000. (Pubitemid 30167724)
37. Sivakumaran M, Vasconcelos ZF, Diamond HR, et al: Modulation of Th1/Th2 subsets by granulocyte-colony stimulating factor. Blood 97: 333-335, 2001.
38. Vasconcelos ZF, Diamond HR, Tabak DG, Barcinski MA and Bonomo A: Th1/Th2 lymphokine profile of T cells present in the blood of granulocyte-colony stimulating factor-treated stem-cell donors: up or down modulation. Blood 95: 333-335, 2001.
39. Arpinati M, Green CL, Heimfeld S, Heuser JE and Anasetti C: Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood 95: 2484-2490, 2000.
40. Ueda Y, Itoh T, Fuji N, et al: Successful induction of clinically competent dendritic cells from granulocyte colony-stimulating factor-mobilized monocytes for cancer vaccine therapy. Cancer Immunol Immunother 8 (e-pub ahead of print), 2006.
41. Szabolcs P, Avigan D, Gezelter S, et al: Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-CFU intermediate. Blood 87: 4520-4530, 1996. (Pubitemid 26162357)
42. Ueda Y, Itoh T, Nukaya I, et al: Dendritic cell-based immunotherapy of cancer with carcinoembryonic antigen-derived, HLA-A24-restricted CTL epitope: clinical outcomes of 18 cases with metastatic gastrointestinal or lung adenocarcinomas. Int J Oncol 24: 909-918, 2004.
43. Young JW: Dendritic cells: expansion and differentiation with hematopoietic growth factors. Curr Opin Hematol 6: 135-144, 1999.
44. Romani N, Gruner S, Brang D, et al: Proliferating dendritic cell progenitors in human blood. J Exp Med 180: 83-93, 1994.
45. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNFα. J Exp Med 184: 695-706, 1996.
46. Lyman SD: Biologic effects and potential clinical application of FLT-3 ligand. Curr Opin Hematol 5: 192-196, 1998.
47. + bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-α. J Immunol 154: 5851-5861, 1995.
48. Morse MA, Nair S, Fernandez-Casal M, et al: Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. J Clin Oncol 18: 3383-3393, 2000.